Therapy Areas: Respiratory
ArkBio commences Phase II clinical trial of AK0610
30 October 2025 - China-based global biotech company Shanghai Ark Biopharmaceutical Co Ltd (ArkBio) announced on Wednesday the start of a Phase II clinical study of AK0610, a fully human monoclonal an...
BioDlink makes first international shipment of bevacizumab to Colombia
28 October 2025 - BioDlink Biopharm Co Ltd (HK:1875), a CDMO specialising in biologics and bioconjugates (ADCs/XDCs), announced on Monday the first international shipment of its bevacizumab injection ...
FDA expands Merck's Winrevair indication for pulmonary arterial hypertension based on Phase 3 trial results
27 October 2025 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Monday that the US Food and Drug Administration (FDA) has approved an up...
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
23 October 2025 - German pharmaceutical company Boehringer Ingelheim announced on Wednesday that JASCAYD (nerandomilast) has been approved by China's National Medical Products Administration (NMP...
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
23 October 2025 - ACM Biolabs, a Singapore-based clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, on Wednesday reported encouraging early clinical fi...
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
...